Armata Pharmaceuticals Inc. (ARMP) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Armata Pharmaceuticals In...

    AMEX: ARMP · Real-Time Price · USD
    2.85
    -0.12 (-4.04%)
    At close: Sep 05, 2025, 3:58 PM
    2.85
    0.00%
    After-hours: Sep 05, 2025, 05:45 PM EDT

    Armata Pharmaceuticals Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -18.92M -69.05M -36.92M -23.16M
    Depreciation & Amortization
    		 1.32M 972K 892K 1.17M
    Stock-Based Compensation
    		 2.89M 938K 3.1M 2.88M
    Other Working Capital
    		 1.66M -9.69M -3.23M -3.41M
    Other Non-Cash Items
    		 -20.75M 29.36M 171K 60K
    Deferred Income Tax
    		 n/a n/a -171K -1.31M
    Change in Working Capital
    		 -2.1M -9.65M 439K -3.22M
    Operating Cash Flow
    		 -37.55M -47.42M -32.48M -23.57M
    Capital Expenditures
    		 -1.88M -8.14M -2.21M -1.3M
    Cash Acquisitions
    		 n/a n/a n/a n/a
    Purchase of Investments
    		 n/a n/a n/a n/a
    Sales Maturities Of Investments
    		 n/a n/a n/a n/a
    Other Investing Acitivies
    		 n/a 10K n/a n/a
    Investing Cash Flow
    		 -1.88M -8.13M -2.21M -1.3M
    Debt Repayment
    		 34.89M 54.03M n/a n/a
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 -61K -43K -375K -801K
    Financial Cash Flow
    		 34.96M 53.99M 44.02M 25.52M
    Net Cash Flow
    		 -4.47M -1.57M 9.32M 639K
    Free Cash Flow
    		 -39.43M -55.57M -34.69M -24.88M

    Add to Watchlist